SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility as investors react to a full exit by Berkshire Hathaway, a move many in the community view as a poorly timed portfolio shuffle by new management rather than a shift in fundamental value. Despite the dip, many traders are treating the price action as a buying opportunity, pointing to the company's strong earnings outlook and ongoing operational focus on AI integration as reasons to remain bullish.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors await a highly anticipated plenary presentation of extended Phase 3 data for CAN-2409 in prostate cancer at the upcoming AUA Annual Meeting. The community is actively debating the stock's potential for a major re-rating, with discussions centered on long-term treatment durability, institutional accumulation by firms like RTW Investments, and the high-stakes outlook for a future BLA submission.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is experiencing intense volatility and downward pressure as investors rotate out of consumer staples into AI-driven sectors while expressing frustration over recent analyst downgrades. Despite the selling, the community remains deeply divided, with many long-term bulls aggressively loading up on shares and highlighting the company's strong brand loyalty and upcoming earnings as potential catalysts for a sharp recovery.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively promoting their crypto tokens across social channels, leveraging community-driven hype and comparing their project to other trending assets. Community members remain deeply divided, with some enthusiasts rallying for a revival of market interest while others voice strong skepticism regarding the project's history and leadership.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as market participants navigate broader economic concerns surrounding persistent inflation, shifting energy dynamics, and geopolitical tensions, while retail investors continue to debate the effectiveness of long-term indexing against a backdrop of increased volatility.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is drawing attention as investors monitor its role in institutional tokenization, specifically following reports of its involvement in major financial pilots and the launch of new exchange-traded products. While some community members remain focused on long-term utility and scarcity, active discussions reflect a mix of patience for structural adoption and caution surrounding short-term price volatility.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron shares are under pressure following a Phase 3 trial failure for its fianlimab-cemiplimab combo in melanoma, which missed its primary endpoint for progression-free survival. While the company is shifting its oncology pipeline focus, investors are also weighing concerns over stock buybacks failing to provide a floor and uncertainty regarding long-term drug pricing headwinds.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is trending due to a 124% year-over-year revenue surge in its latest fiscal report, driven by intense demand for semiconductor reliability testing in AI and electric vehicle markets. Community sentiment is highly bullish as investors compare the company's strong fundamentals and small float to higher-valued peers, viewing it as a significantly undervalued play in the AI hardware ecosystem.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

Investors are actively debating the sustainability of the current AI-driven market rally, with many drawing parallels to historical tech bubbles as the Nasdaq achieves record winning streaks. The community remains polarized, with bears accumulating leveraged inverse ETFs like SQQQ in anticipation of a significant correction or geopolitical instability, while bulls continue to prioritize momentum and institutional flows.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as bond market participants react to rising inflation, elevated energy costs from geopolitical tensions, and concerns over the surging U.S. national debt-to-GDP ratio. The community is sharply divided, with some investors aggressively accumulating positions in anticipation of a potential rate-cutting cycle, while others view the bond market's decline as a sign of long-term economic instability and fiscal mismanagement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Ainos (NASDAQ:AIMD) Major Shareholder Sells 46,000 Shares of Stock

Ainos, Inc. (NASDAQ:AIMD - Get Free Report) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the stock in a transaction dated Wednesday, January 28th. The stock was sold at an...

Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotechnology company based in San Diego, California, pioneering the digitization of scent with its proprietary AI Nose platform and advancing immune therapeutics. Their AI Nose technology, powered by a breakthrough smell language model, enables machine olfaction for applications in industries such as semiconductor manufacturing, robotics, smart factories, senior care, and women’s health. The company is also developing VELDONA, a low-dose oral interferon alpha with clinical programs targeting rare, autoimmune, and infectious diseases for both humans and animals. With recent industrial deployments and recurring revenue contracts in Asia, Ainos aims to transform diagnostics, preventive medicine, and industrial monitoring through innovative SmellTech and biotech solutions.

AIMD
Ainos Inc

Feed

News

Sentiment

Fundamentals

Info

Latest AIMD News

AIMDAinos Inc